NCT06235801 2025-11-19A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 1/2 Recruiting20 enrolled
NCT05282459 2025-03-20Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 MutationStanford UniversityPhase 1/2 Completed17 enrolled